Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.

NPJ Precis Oncol · 2024 · PMC11291882 · PMID 39085400

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

indeterminate significanceno p-value reported

Two patients from cohort 2 harbored PTEN mutations of indeterminate significance and were excluded from the overall survival (OS) and progression-free survival (PFS) evaluations.

also in 137 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.